17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women.

Forty women aged 64.7 +/- 5.1 yr with established postmenopausal osteoporosis were blindly allocated to 1 yr's treatment with either continuous combined estrogen/progestogen therapy (2 mg estradiol + 1 mg norethisterone acetate + 500 mg calcium daily) or placebo + 500 mg calcium daily. In the group treated with hormones bone mineral density in the spine (dual photon absorptiometry) and bone mineral content in the ultradistal forearm (single photon absorptiometry) increased highly significantly by 8-10% during the 1 yr of treatment. Bone mineral content in the mid-shaft of the forearm (single photon absorptiometry) and the total body bone mineral (dual photon absorptiometry) increased by 3-5% when compared to that in the placebo group, which showed virtually unchanged values at all measurement sites. Seven of the women treated with hormones were examined after a further year of treatment. BMC increased by another 3-6%, reaching a 12% increase in bone mineral density in the spine after 2 yr of treatment. Biochemical estimates of bone resorption (fasting urinary calcium and hydroxyproline) and bone formation (serum alkaline phosphatase and plasma osteocalcin), decreased significantly (P less than 0.001) in the group treated with hormones, but remained unchanged in the placebo group. The reduction in indices of bone resorption was more pronounced than that in bone formation after one year, indicating a positive bone balance. No further changes were seen in these bone turnover parameters during the second year of treatment. In the group treated with hormones, serum levels of triglycerides, total cholesterol, and low density lipoprotein cholesterol decreased by about 12% (P less than 0.05-P less than 0.01), whereas high density lipoprotein cholesterol decreased by about 8% (P less than 0.001). The high density lipoprotein cholesterol/low density lipoprotein cholesterol ratio was unchanged. The hormone treatment did not produce any major side effects, and only minor bleedings were experienced by a few women. The present study demonstrates that treatment with female sex hormones in this particular combination is a realistic approach to the treatment of women with established postmenopausal osteoporosis.

[1]  C. Christiansen,et al.  Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? , 1990, The Journal of clinical endocrinology and metabolism.

[2]  S. H. Kan,et al.  Epidemiology of vertebral fractures in women. , 1989, American journal of epidemiology.

[3]  C. Christiansen,et al.  Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate? , 1989, Bone and mineral.

[4]  C. Christiansen,et al.  NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSIS , 1989, Clinical endocrinology.

[5]  C. Christiansen,et al.  Iliac crest biopsy in longitudinal therapeutic trials of osteoporosis. , 1988, Bone and mineral.

[6]  L. Mattsson,et al.  Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints , 1988, British journal of obstetrics and gynaecology.

[7]  S. P. Nielsen,et al.  Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study , 1988, British medical journal.

[8]  C. Christiansen,et al.  CYPROTERONE ACETATE, AN ALTERNATIVE GESTAGEN IN POSTMENOPAUSAL OESTROGEN/GESTAGEN THERAPY , 1987, Clinical endocrinology.

[9]  C. Christiansen,et al.  A radioimmunoassay for bone Gla protein (BGP) in human plasma. , 1987, Acta endocrinologica.

[10]  C. Christiansen,et al.  The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. , 1987, American journal of obstetrics and gynecology.

[11]  P. Geusens,et al.  Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. , 1986, Bone and Mineral.

[12]  C. Christiansen,et al.  Comparison of single- and dual-photon absorptiometry in postmenopausal bone mineral loss. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  C. Christiansen,et al.  UNCOUPLING OF BONE FORMATION AND RESORPTION BY COMBINED OESTROGEN AND PROGESTAGEN THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS , 1985, The Lancet.

[14]  H. Genant,et al.  Long-term estrogen replacement therapy prevents bone loss and fractures. , 1985, Annals of internal medicine.

[15]  R B Mazess,et al.  Total body bone mineral in vivo by dual photon absorptiometry. I. Measurement procedures. , 1984, Clinical physiology.

[16]  W. Nelp,et al.  Long-term calcitonin therapy in postmenopausal osteoporosis. , 1984, Metabolism: clinical and experimental.

[17]  C. Christiansen,et al.  Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. , 1982, Clinical orthopaedics and related research.

[18]  C. Christiansen,et al.  TREATMENT OF POST MENOPAUSAL OSTEOPOROSIS. A CONTROLLED THERAPEUTIC TRIAL COMPARING OESTROGEN/GESTAGEN, 1,25‐DIHYDROXY‐VITAMIN D3 AND CALCIUM , 1982, Clinical endocrinology.

[19]  B. Staland.  Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. , 1981, Maturitas.

[20]  C. Christiansen,et al.  BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPY , 1981, The Lancet.

[21]  N. Weiss,et al.  Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. , 1980, The New England journal of medicine.

[22]  R. Schifman,et al.  Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement. , 1978, Clinical chemistry.

[23]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.